Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

License Agreements (Details)			1 Months Ended	3 Months Ended		9 Months Ended
License Agreements (Details)	Feb. 16, 2018 USD ($) unit	Dec. 18, 2015 USD ($) unit	Nov. 30, 2017 USD ($) $ / unit	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Oct. 31, 2017
Asset Acquisition And License Agreement [Line Items]
Noncontrolling interest ownership percentage by Noncontrolling Owners								10.00%
Cost of product sales				$ 3,111,290	$ 0	$ 5,397,872	$ 0
Ulesfia Supply Agreement
Asset Acquisition And License Agreement [Line Items]
License obligation				6,900,000		6,900,000
Indemnity receivable				6,100,000		6,100,000
Cost of product sales				$ 1,700,000		$ 1,700,000
TRIS Pharma \| Karbinal Agreement
Asset Acquisition And License Agreement [Line Items]
Minimum quantity required \| unit	70,000
Product royalty	23.50%
Contract term	20 years
Product royalty, net	15.00%
Potential milestone revenue threshold	$ 40,000,000
Potential milestone payment	$ 3,000,000
Avadel \| Karbinal Agreement
Asset Acquisition And License Agreement [Line Items]
Make whole payment, percent	8.50%
Eisai Inc \| AcipHex Agreement
Asset Acquisition And License Agreement [Line Items]
Product royalty	15.00%
Potential milestone revenue threshold	$ 50,000,000
Yung Shin Pharm. Ind, Co \| Cefaclor
Asset Acquisition And License Agreement [Line Items]
Product royalty	15.00%
Potential milestone revenue threshold	$ 40,000,000
Automatic renewal period	12 months
Maximum \| TRIS Pharma \| Karbinal Agreement
Asset Acquisition And License Agreement [Line Items]
Make whole payment	$ 750,000
Maximum \| Eisai Inc \| AcipHex Agreement
Asset Acquisition And License Agreement [Line Items]
Potential milestone payment	$ 8,000,000.0
Royalty payment period	5 years
Maximum \| Yung Shin Pharm. Ind, Co \| Cefaclor
Asset Acquisition And License Agreement [Line Items]
Potential milestone payment	$ 6,500,000.0
Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Asset Acquisition And License Agreement [Line Items]
Indemnification of pre-acquisition losses (as a percent)			100.00%
Indemnification of post-acquisition losses, (as a percent)			50.00%
Lachlan Pharmaceuticals \| Minimum \| Ulesfia Supply Agreement
Asset Acquisition And License Agreement [Line Items]
Threshold indemnification of legal costs and possible minimum payments			$ 1,000,000
Zylera \| Ulesfia Supply Agreement
Asset Acquisition And License Agreement [Line Items]
Price (in dollars per unit) \| $ / unit			58.84
Management and handling fee (in dollars per unit) \| $ / unit			3.66
Management and handling fee annual price increase			10.00%
Zylera \| Lachlan Pharmaceuticals \| Ulesfia Supply Agreement
Asset Acquisition And License Agreement [Line Items]
Minimum quantity required \| unit		20,000
Long-term purchase commitment		$ 1,200,000
Minimum royalty		$ 3,000,000
Indemnification of post-acquisition losses, (as a percent)						50.00%